花旗发表研究报告指,再鼎医药(09688.HK) -0.180 (-1.042%) 沽空 $1.34亿; 比率 19.425% 第三季总收入约为1.16亿美元,分别较该行及市场预测低16%和22%。再鼎医药管理层大削今年收入指引目标,由之前的5.6亿至5.9亿美元,降至至少4.6亿美元,并移除今年达到营运开支平衡的目标。该行估计,再鼎医药今年的产品总收入约为4.57亿美元,考虑到中国...
Source Link花旗发表研究报告指,再鼎医药(09688.HK) -0.180 (-1.042%) 沽空 $1.34亿; 比率 19.425% 第三季总收入约为1.16亿美元,分别较该行及市场预测低16%和22%。再鼎医药管理层大削今年收入指引目标,由之前的5.6亿至5.9亿美元,降至至少4.6亿美元,并移除今年达到营运开支平衡的目标。该行估计,再鼎医药今年的产品总收入约为4.57亿美元,考虑到中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.